Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
51.8 PLN | +6.58% | +6.04% | -9.91% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.91% | 280M | - | ||
+9.15% | 105B | B+ | ||
-1.08% | 104B | B+ | ||
+5.79% | 22.94B | B | ||
-11.55% | 22.34B | B+ | ||
-7.01% | 19.25B | A- | ||
-37.08% | 17.08B | A- | ||
-9.91% | 16.96B | B | ||
+7.55% | 14.16B | C+ | ||
+40.04% | 12.63B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- RVU Stock
- Ratings Ryvu Therapeutics S.A.